Elevated opioid activity in sera of chronic schizophrenics

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Schizophrenia is a complex mental disorder with poorly understood biological underpinnings.
• Opioid systems are implicated in various neurological and psychiatric conditions.
• Investigating serum components may reveal biomarkers for schizophrenia.

Purpose of the Study:

• To investigate the effect of serum from schizophrenic patients on isolated mouse vas deferens (MVD) contractions.
• To identify and characterize the active components in schizophrenic serum responsible for observed effects.
• To explore potential opioid involvement in the pathophysiology of schizophrenia.

Main Methods:

• Electrically induced contractions of isolated mouse vas deferens (MVD) preparations.
• Testing native serum samples from schizophrenic patients, healthy controls, and other mentally ill patients.
• Ultrafiltration and gel chromatography for fractionating active serum components.
• Chemical analysis (ninhydrin, Lowry) and molecular mass determination (0.5-5.0 KD) of active fractions.

Main Results:

• Serum from schizophrenic patients, but not controls, caused naloxone-dependent inhibition of MVD contractions.
• Four biologically active fractions were isolated from schizophrenic serum.
• Active fractions contained elevated levels of ninhydrin/Lowry-positive materials and unidentified carbohydrates.
• The active serum ingredients possess opioid activity and molecular masses between 0.5 and 5.0 KD.

Conclusions:

• Schizophrenic serum contains specific opioid-active peptides and glycopeptides that inhibit MVD contractions.
• These findings suggest that the presence or accumulation of these novel opioid substances may be characteristic of schizophrenia.
• Further research into these compounds could provide novel diagnostic or therapeutic targets for schizophrenia.